Regeneron Pharmaceuticals (REGN) Tax Provisions (2011 - 2026)

Regeneron Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $230.9 million for Q2 2026.

• In Q2 2026, Tax Provisions rose 81.67% year-over-year to $230.9 million; the TTM figure through Jun 2026 stood at $837.3 million (up 101.18% YoY), while the FY2025 annual figure was $725.8 million, up 97.6% from the prior year.
• Tax Provisions for Q2 2026 stood at $230.9 million, up from $104.0 million in the prior quarter.
• The five-year high for Tax Provisions was $303.3 million in Q3 2025, with the low at -$21.3 million in Q1 2024.
• The 5-year median for Tax Provisions is $112.8 million (2022), against an average of $121.9 million.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions sank 152.99% in 2024, then soared 552.11% in 2025.
• Regeneron Pharmaceuticals' Tax Provisions stood at $127.6 million in 2022, then slumped by 109.4% to -$12.0 million in 2023, then soared by 436.67% to $40.4 million in 2024, then surged by 392.82% to $199.1 million in 2025, then grew by 15.97% to $230.9 million in 2026.
• Business Quant data shows REGN's Tax Provisions at $230.9 million in Q2 2026, $104.0 million in Q1 2026, and $199.1 million in Q4 2025.